Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 8/20 | 0.62 |
| ▸ | GSK3A | P49840 | 4/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.62 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | PLK4 | O00444 | 3/20 | 0.62 |
| ▸ | AURKA | O14965 | 3/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.62 |
| ▸ | STK3 | Q13188 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178865 | 0.89 | CYP1A2 (0.80) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL2420515 | 0.87 | CYP1A2 (0.77) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL8791690 | 0.83 | ALDH1A1 (0.76) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL11807411 | 0.83 | CYP1A2 (0.71) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL30259191 | 0.82 | ALDH1A1 (0.70) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL30259055 | 0.82 | ALDH1A1 (0.70) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL30258763 | 0.82 | CYP1A2 (0.70) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL8791662 | 0.82 | CYP1A2 (0.70) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL9793307 | 0.80 | CYP1A2 (0.67) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL8790953 | 0.79 | CYP1A2 (0.65) | CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000059-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006403-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| EP-0393604-B1 | 6,11-Dihydro-5H-pyrido(2,3-b)(1,5,)benzodiazepin-5-ones and thiones and their use in the prevention or treatment of AIDS | BOEHRINGER INGELHEIM PHARMA (US) | 1997-12-29 | — | — | EP | claimed |
| US-5571809-A | The treatment of HIV-1 infection using certain pyridodiazepines | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-11-05 | — | — | US | claimed |
| US-5001122-A | Use of diazepinones for treating disorders of the microcirculation | DR. KARL THOMAE GMBH (DE) | 1991-03-19 | — | — | US | claimed |
| EP-0342474-A2 | Use of diazepinones for the preparation of a medicament for therapy of microcirculatory disorders | Dr. Karl Thomae GmbH (DE) | 1989-11-23 | — | — | EP | claimed |
| US-4841046-A | Process for the preparation of pyridobenzodiazepinone | DOMPE' FARMACEUTICI S.P.A. (IT) | 1989-06-20 | — | — | US | claimed |
| EP-0314163-A2 | Process for the preparation of 6,11-dihydro-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one | DOMPE' FARMACEUTICI S.p.A. (IT) | 1989-05-03 | — | — | EP | claimed |
| JP-3063274-A | — | — | None | — | — | JP | disclosed |
| WO-2023020416-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2023-02-23 | — | — | WO | disclosed |
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3226690-B1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-0314163-A2 | Process for the preparation of 6,11-dihydro-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one | DOMPE' FARMACEUTICI S.p.A. (IT) | 1989-05-03 | — | — | EP | disclosed |
| US-4594190-A | Quaternary salts of dibenzo[1,4]diazepinones, pyrido-[1,4]benzodiazepinones, pyrido[1,5]benzodiazepinones with antiulcer, antisecretory, spasmolytic and antimusarinic activities | DOMPE' FARMACEUTICI S.P.A. (IT) | 1986-06-10 | — | — | US | disclosed |
| US-4556653-A | ANTISECRETORY, ANTIULCER AND ANTISPASMODIC AGENTS | DOMPE' FARMACEUTICA S.P.A. (IT) | 1985-12-03 | — | — | US | disclosed |
| EP-0126366-A2 | Quaternary salts of dibenzo(1,4)diazepinone, pyrido-(1,4)benzodiazepinone, pyrido(1,5)benzodiazepinone derivatives and pharmacological activity thereof | DOMPE' FARMACEUTICI S.p.A. (IT) | 1984-11-28 | — | — | EP | disclosed |
| US-4167570-A | BRONCHOSPASMOLYTICS, BRONCHOSECRETOLYTICS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-09-11 | — | — | US | disclosed |
| US-4021557-A | BRONCHOSPASMOLYTICS | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH2, IDH3B | CYP1A2 146/4885SMN1; SMN2 3984/4885ALDH1A1 92/4885 |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH3B, IDH2 | CYP1A2 157/4885SMN1; SMN2 3733/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.